Zymeworks (NASDAQ:ZYME) Price Target Raised to $47.00

Zymeworks (NASDAQ:ZYME) had its price target boosted by Stifel Nicolaus from $40.00 to $47.00 in a research note released on Tuesday,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

A number of other analysts have also recently commented on ZYME. Citigroup initiated coverage on Zymeworks in a research report on Wednesday, December 3rd. They issued an “outperform” rating for the company. Wells Fargo & Company raised shares of Zymeworks from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $25.00 to $33.00 in a research note on Friday, December 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Zymeworks in a research report on Wednesday, January 21st. Wall Street Zen lowered shares of Zymeworks from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, HC Wainwright boosted their target price on shares of Zymeworks from $26.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $35.70.

Zymeworks Stock Performance

Shares of Zymeworks stock opened at $24.80 on Tuesday. The firm has a 50-day simple moving average of $23.78 and a two-hundred day simple moving average of $21.01. Zymeworks has a fifty-two week low of $9.03 and a fifty-two week high of $28.49. The company has a market cap of $1.83 billion, a P/E ratio of -22.96 and a beta of 1.23.

Zymeworks (NASDAQ:ZYME) last posted its earnings results on Monday, March 2nd. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.20). The business had revenue of $2.52 million for the quarter, compared to analyst estimates of $21.78 million. Zymeworks had a negative net margin of 76.56% and a negative return on equity of 26.00%. Zymeworks’s revenue was down 91.9% on a year-over-year basis. During the same quarter last year, the business earned ($0.31) earnings per share.

Insider Transactions at Zymeworks

In other Zymeworks news, COO Mark Hollywood sold 6,120 shares of Zymeworks stock in a transaction on Monday, January 12th. The shares were sold at an average price of $22.67, for a total transaction of $138,740.40. Following the sale, the chief operating officer owned 132,913 shares of the company’s stock, valued at $3,013,137.71. The trade was a 4.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Jeffrey T. L. Smith sold 10,538 shares of the company’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $25.10, for a total transaction of $264,503.80. Following the sale, the executive vice president directly owned 18,352 shares of the company’s stock, valued at $460,635.20. The trade was a 36.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 187,933 shares of company stock worth $4,673,716. Company insiders own 33.51% of the company’s stock.

Institutional Trading of Zymeworks

Several large investors have recently bought and sold shares of the business. EcoR1 Capital LLC grew its position in Zymeworks by 33.1% in the second quarter. EcoR1 Capital LLC now owns 22,970,388 shares of the company’s stock worth $288,278,000 after acquiring an additional 5,710,840 shares during the period. Rubric Capital Management LP lifted its stake in shares of Zymeworks by 22.1% in the 4th quarter. Rubric Capital Management LP now owns 5,750,000 shares of the company’s stock valued at $151,398,000 after purchasing an additional 1,039,449 shares during the last quarter. Perceptive Advisors LLC grew its holdings in shares of Zymeworks by 56.0% during the 4th quarter. Perceptive Advisors LLC now owns 3,261,850 shares of the company’s stock worth $85,885,000 after purchasing an additional 1,171,187 shares during the period. Vanguard Group Inc. increased its position in shares of Zymeworks by 8.1% during the 4th quarter. Vanguard Group Inc. now owns 2,328,727 shares of the company’s stock worth $61,315,000 after purchasing an additional 174,293 shares during the last quarter. Finally, Vestal Point Capital LP increased its position in shares of Zymeworks by 53.5% during the 3rd quarter. Vestal Point Capital LP now owns 1,765,000 shares of the company’s stock worth $30,146,000 after purchasing an additional 615,000 shares during the last quarter. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Key Headlines Impacting Zymeworks

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: Lifesci Capital raised several later-quarter and full‑year FY2026 EPS estimates (Q2, Q3, Q4 and FY2026 were revised to be materially less negative or positive), signaling improving expectations for Zymeworks’ 2026 profitability outlook. MarketBeat Analyst Note
• Positive Sentiment: Stifel Nicolaus boosted its price target to $47, and Leerink issued a bullish outlook — analyst upgrades and higher targets support upside sentiment and explain earlier intraday gains. Stifel Price Target Leerink Note
• Positive Sentiment: Media noted a short-term positive reaction to analyst upgrades (shares rose on upgrade headlines). Upgrade Reaction
• Neutral Sentiment: Consensus analyst stance remains constructive overall (average recommendation ~“Moderate Buy”), which provides informational support but not immediate fundamental change. Analyst Consensus
• Negative Sentiment: Recent Q4 results were a clear negative catalyst: EPS missed and revenue plunged year‑over‑year (top-line far below expectations), highlighting the volatility of Zymeworks’ milestone-driven model and near-term execution risk. This underpins profit worries despite longer-term analyst upgrades. FY25 Review / Q4 Analysis
• Negative Sentiment: Lifesci also lowered its Q1 2026 EPS forecast (from a prior positive to a negative), signaling near-term softness that likely offsets some of the enthusiasm from later‑year upgrades. MarketBeat Analyst Note

Zymeworks Company Profile

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.